

Applicant: Peter S. Mueller
Application Serial No.: Unassigned
Filing Date: Unassigned
Docket No.: 893-2 CIP II DIV
Page 3

B. Amendments to the Claims

Claim 1. (Original) A method for enhancing or stimulating neurogenesis comprising administering to a human in need of such treatment a pharmaceutically effective amount of a compound which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine.

Claim 2. (Cancelled)

Claim 3. (Original) The method of claim 1 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.

Claim 4. (Cancelled)

Claim 5. (Original) A method for treatment of symptoms of Cerebral Palsy comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 6. (Original) The method of claim 5 wherein the symptoms include spasticity.

Claim 7. (Original) The method of claim 5 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.

Applicant: Peter S. Mueller
Application Serial No.: Unassigned
Filing Date: Unassigned
Docket No.: 893-2 CIP II DIV
Page 4

Claims 8-9. (Cancelled)

Claim 10. (Original) A method for treatment of symptoms of Torticollis comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 11. (Original) The method of claim 10 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.

Claims 12-17 (Cancelled)

Claim 18. (Original) A method for treatment of symptoms of Dyskinesia, Tardive Dyskinesia, Lingual Dyskinesia and Facial Dyskinesia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 19. (Original) The method of claim 18 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.

Claims 20-21. (Cancelled)

Applicant: Peter S. Mueller
Application Serial No.: Unassigned
Filing Date: Unassigned
Docket No.: 893-2 CIP II DIV
Page 5

Claim 22. (Original) A method for treatment of symptoms of Institutionalization Syndrome and Concentration Camp Syndrome comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 23. (Original) The method of claim 22 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.

Claims 24-25. (Cancelled)

Claim 26. (Original) A method for treatment of symptoms of Dementia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 27. (Original) The method of claim 26 wherein the Dementia is Alzheimer's dementia or non-Alzheimer's dementia.

Claim 28. (Original) The method of claim 26 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.

Applicant: Peter S. Mueller
Application Serial No.: Unassigned
Filing Date: Unassigned
Docket No.: 893-2 CIP II DIV
Page 6

Claims 29-30. (Cancelled)

Claim 31. (New) A method of treatment for neurological, behavioral and cognitive disorders or symptoms, emanating from primary organic impairments which comprise temporal lobe epilepsy; brain disorders of metabolic, endocrine, genetic, or chromosomal diseases, brain cysts and tumors; or viral infection, said method comprising administering to a human in need of such treatment a pharmaceutically effective amount of sibutramine, sibutramine salts or derivatives of sibutramine which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine.

Claim 32. (New) The method of Claim 31 wherein the treatment interrupts endorphin-opioid pathology.

Claim 33. (New) A method for treatment of symptoms of Sick Building Syndrome comprising administering a pharmaceutically effective amount of sibutramine, sibutramine salts or derivatives of sibutramine which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 34. (New) A method for treatment of symptoms of Gulf War Syndrome comprising administering a pharmaceutically effective amount of sibutramine, sibutramine salts or derivatives of sibutramine which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Applicant: Peter S. Mueller
Application Serial No.: Unassigned
Filing Date: Unassigned
Docket No.: 893-2 CIP II DIV
Page 7

Claim 35. (New) A method for treatment of symptoms of Reflex Sympathetic Dystrophy Syndrome or Complex Regional Pain Syndrome comprising administering a pharmaceutically effective amount of sibutramine, sibutramine salts or derivatives of sibutramine which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 36. (New) A method for treatment of claims 35 wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.

Claim 37. (New) A method for treatment of claims 35 further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.

Claim 38. (New) The method for treatment of claims 35 further including an antiepileptic or anti-depressant medication.

Claim 39. (New) A method for treatment of symptoms of Retinitis Pigmentosa comprising administering a pharmaceutically effective amount of sibutramine, sibutramine salts or derivatives of sibutramine which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Applicant: Peter S. Mueller
Application Serial No.: Unassigned
Filing Date: Unassigned
Docket No.: 893-2 CIP II DIV
Page 8

Claim 40. (New) A method for treatment of symptoms of organic brain impairments which result in stammering comprising administering a pharmaceutically effective amount of sibutramine, sibutramine salts or derivatives of sibutramine which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

Claim 41. (New) A method for treatment of adult or adolescent sexual disorders comprising administering a pharmaceutically effective amount of sibutramine, sibutramine salts or - derivatives of sibutramine which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.